Loading...
XNAS
PYXS
Market cap71mUSD
Jul 11, Last price  
1.16USD
1D
-2.52%
1Q
21.00%
IPO
-90.33%
Name

Pyxis Oncology Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
4.45
EPS
Div Yield, %
Shrs. gr., 5y
11.24%
Rev. gr., 5y
%
Revenues
16m
0000016,146,000
Net income
-77m
L+4.80%
-2,665,000-12,762,000-81,536,000-117,953,000-73,790,000-77,331,000
CFO
-58m
L-18.44%
-2,239,000-10,084,000-35,326,000-89,335,000-70,709,000-57,672,000

Profile

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
IPO date
Oct 08, 2021
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
16,146
 
Cost of revenue
84,642
84,196
125,317
Unusual Expense (Income)
NOPBT
(68,496)
(84,196)
(125,317)
NOPBT Margin
Operating Taxes
(2,164)
(2,764)
Tax Rate
NOPAT
(66,332)
(84,196)
(122,553)
Net income
(77,331)
4.80%
(73,790)
-37.44%
(117,953)
44.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,046
6,122
183
BB yield
-64.76%
-8.52%
-0.41%
Debt
Debt current
1,450
2,464
Long-term debt
38,950
41,430
37,842
Deferred revenue
Other long-term liabilities
Net debt
(86,531)
(75,404)
(141,451)
Cash flow
Cash from operating activities
(57,672)
(70,709)
(89,335)
CAPEX
(237)
(6,726)
(6,399)
Cash from investing activities
8,155
(104,849)
(6,399)
Cash from financing activities
59,326
5,929
183
FCF
(63,659)
(84,243)
(146,081)
Balance
Cash
126,931
119,298
179,293
Long term investments
Excess cash
126,124
119,298
179,293
Stockholders' equity
(363,326)
(286,117)
(212,401)
Invested Capital
504,277
434,384
392,146
ROIC
ROCE
EV
Common stock shares outstanding
58,446
39,905
33,033
Price
1.56
-13.33%
1.80
34.33%
1.34
-87.78%
Market cap
91,175
26.94%
71,828
62.27%
44,264
-87.48%
EV
4,644
(3,576)
(97,187)
EBITDA
(65,514)
(82,269)
(124,608)
EV/EBITDA
0.04
0.78
Interest
2,764
Interest/NOPBT